BOSTON SCIENTIFIC LIMITED

1. BOSTON SCIENTIFIC LIMITED 1992-07-27 → present
2. BESTDANE LIMITED 1992-07-08 → 1992-07-27

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The company has an excess of current assets over current liabilities of £19,143k at 31 December 2024 (2023: £9,979k) and continues to generate substantial cash from its UK and Irish operations through 2024. As evidenced by the company's steady growth over recent years, our business model is strong and cash-generative, with established customer relationships and access to market intelligence, and while risks exist as discussed in the Strategic Report, to date nothing exists that suggests a material threat to that position. The Director has carried out a detailed review of revised cash flow forecasts covering at least 12 months from the date of approval of these financial statements, and has concluded, after applying reasonable sensitivities and assumptions to those forecasts, that the company is able to generate sufficient cash flows from its operations to maintain its business through that period. In addition, the company is a member of global corporate cash pooling by means of a Demand Facility Agreement which entitles it to freely draw on Group funds in its day-to-day operations, up to a limit which the Director believes would cover the company's liabilities even under severe financial circumstances. On the basis that the company partly relies on intercompany funding as a participant of the group cash pooling arrangement, the company has obtained a letter of support from Boston Scientific Corporation, the ultimate parent company. The letter confirms that the company will receive the necessary financial support to assist the company to meet its liabilities as and when they fall due for the period of 12 months from the date of approval of the financial statements for the year ended 31 December 2024. After making these enquiries, the Director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, the director continues to adopt the going concern basis in preparing these financial statements.”

Significant events

• “In December 2024, the company became aware of a Field Safety Notification (FSN) which is likely to result in an early replacement of medical units across UK. In March 2025, the company undertook a further assessment of the situation, and on the premise that this provides evidence of a condition that existed prior to the reporting date, the company has decided to make a provision in the 2024 Financial Statements. This provision reflects the future, probable outflow of funds associated with this Field Safety Notification.”
• “On 1 May 2025, as part of Boston Scientific's global integration of the Axonics UK business, the company acquired the UK trade and assets & liabilities of Axonics Women's Health Limited & Axonics Modulation Technologies, U.K. Limited, for £3,833k which was financed through an intercompany loan. In accordance with FRS 102 section 19, the company valued the assets and liabilities acquired at their fair value on the date of acquisition and recorded the excess of the cost of the combination over and above this value as goodwill.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

4

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +7.9%

  £285,301,000 → £307,982,000

• Cash

  -89.2%

  £288,000 → £31,000

• Net assets

  +20.8%

  £39,547,000 → £47,775,000

• Employees

  +5%

  443 → 465

• Operating profit

  +27%

  £6,854,000 → £8,702,000

• Profit before tax

  +32.6%

  £6,706,000 → £8,890,000

• Wages

  +6.3%

  £39,232,000 → £41,715,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers